Guardant Health
Korean AI Pathology Startup Lunit Nabs $26M Investment from Guardant Health; Plans Collaboration
Having closed a Series C funding round, the firm is completing clinical validation, and will collaborate with Guardant to develop new precision oncology products.
The firm announced the new test, Guardant360 Response, alongside its launch of its Guardant360 TissueNext tumor tissue genomic profiling product.
FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen
The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.
Guardant Health Sues Natera for False Advertising, 'Misleading' Oncologists About MRD Tests
Guardant has asked the court to recover damages and to prevent Natera from further disseminating "deceptive" advertising regarding their competing assays.
FDA Approves Janssen's Rybrevant, Guardant360 CDx for EGFR Exon 20-Mutated NSCLC
The agency approved amivantamab for non-small cell lung cancer patients harboring EGFR exon 20 mutations, as detected by Guardant Health's blood-based test.
Feb 5, 2021